Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
Biocytogen Pharmaceuticals Grants Worldwide License for Anti-Tumor Therapy
BeiGene (02315.HK) nominated IDEAYA first-in-class potential B7H3/PTK7 as a candidate drug for development.
Bay Area Stock B (02315.HK) announced that IDEAYA Biosciences (IDYA.US) has exercised its option to obtain the global exclusive license for the novel B7H3/PTK7 topoisomerase inhibitor effective payload bispecific antibody drug BCG034, which has similar pioneering potential as the company. The project has been nominated as a development candidate drug. Under the agreement, the company will receive an upfront payment and option exercise fee, additional development and regulatory milestone payments, commercial milestone payments, and net sales royalties, totaling up to 0.4065 billion US dollars, including up to 0.1 billion US dollars.
IDEAYA Biosciences: Strategic Initiatives and Growth Potential Reinforce Buy Rating
IDEAYA Licenses Biocytogen's Antibody Program for Cancer Treatment, Eyes FDA Submission in 2025